| Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women. | |
| | |
MedLine Citation:
|
PMID: 7517835 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This multicentre open 6-week study evaluated the efficacy, safety and tolerability of fluvastatin, the first fully synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor, in elderly women with type IIa hypercholesterolaemia. After a 4-week single-blind placebo period, 22 elderly women (mean age 68 +/- 5 years) with primary hypercholesterolaemia [low density lipoprotein (LDL) cholesterol > 160 mg/dl] were enrolled in the trial. Fluvastatin 40 mg was administered once in the evening. At baseline, and after 3 and 6 weeks of treatment, total cholesterol, LDL cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides, apolipoproteins B (apo B) and A-I (apo A-I) were measured. Safety and tolerability were assessed by monitoring routine laboratory parameters and by recording spontaneously reported side effects. The mean (+/- SD) baseline total cholesterol, LDL cholesterol, triglyceride, HDL cholesterol, apo B and apo A-I levels were 325 +/- 43, 236 +/- 43, 128 +/- 56, 61 +/- 16, 221 +/- 60 and 164 +/- 28 mg/dl, respectively. After 6 weeks, fluvastatin significantly (p < 0.001, ANOVA test) reduced total cholesterol, LDL cholesterol and apo B levels by 22%, 29% and 23%, respectively. These significant reductions were already reached at week 3 (total cholesterol, -21%; LDL cholesterol, -27%). The total cholesterol: HDL cholesterol ratio was reduced by 22% at week 3 and by 21% at week 6 (from 5.3 to 4.2). 78% of the patients showed a reduction > or = 20% for LDL cholesterol. Triglycerides were reduced by 16% (not significant).(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
G Baggio; O De Candia; P L Forte; F Mello; A Andriolli; S Donazzan; G Valerio; M Milani; G Crepaldi |
Related Documents
:
|
3606725 - Effects of pure capsaicinoids (capsaicin and dihydrocapsaicin) on plasma lipid and lipo... 16280425 - Individual variability in cardiovascular disease risk factor responses to low-fat and l... 11157605 - Relationship between pleural fluid and serum cholesterol levels. 20666105 - Atherogenic dyslipidemia--a medical underwriter's iceberg. 4045455 - Partial restoration of cerebral myelination of the congenitally hypothyroid mouse by pa... 20671425 - Gestational low protein diet in the rat mediates igf2 gene expression in male offspring... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study |
Journal Detail:
|
Title: Drugs Volume: 47 Suppl 2 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 1994 |
Date Detail:
|
Created Date: 1994-08-09 Completed Date: 1994-08-09 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 59-63 Citation Subset: IM |
Affiliation:
|
Institute of Internal Medicine, University of Padua, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Cholesterol / blood Fatty Acids, Monounsaturated / therapeutic use* Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors* Hyperlipoproteinemia Type II / drug therapy* Indoles / therapeutic use* Lipids / blood |
| Chemical | |
Reg. No./Substance:
|
0/Fatty Acids, Monounsaturated; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Indoles; 0/Lipids; 57-88-5/Cholesterol; 93957-54-1/fluvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gender-related response to fluvastatin in patients with heterozygous familial hypercholesterolaemia.
Next Document: Efficacy and safety of fluvastatin in women with primary hypercholesterolaemia.